Recently, studies employing genetic ablation of TMEM30A in leukemia cells render these cells constitutively PS positive and resistant to NK-mediated degranulation and cell killing, suggesting that PS externalization may serve as an immune-evasive strategy in malignancies [58]. The gene discussed is CDC50A; the disease is cancer.